ERC1671 vaccine randomized phase 2 trial results - Hallo friendsTOP POLENNEWS, In the article you read this time with the title ERC1671 vaccine randomized phase 2 trial results, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cultur, Article economic, Article health, Article news, Article politique, Article sport, We write this you can understand. Alright, good read.

Title : ERC1671 vaccine randomized phase 2 trial results
link : ERC1671 vaccine randomized phase 2 trial results

ERC1671 vaccine randomized phase 2 trial results

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.

Median overall survival (OS) of patients treated with ERC1671 plus bevacizumab was 12 months. In the placebo plus bevacizumab group, median OS was 7.5 months. The maximal CD4+ T-lymphocyte count correlated with OS in the ERC1671 but not in the placebo group.

CONCLUSION:

The addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity.

Thus Article ERC1671 vaccine randomized phase 2 trial results

That's an article ERC1671 vaccine randomized phase 2 trial results This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article ERC1671 vaccine randomized phase 2 trial results with the link address https://polennews.blogspot.com/2018/08/erc1671-vaccine-randomized-phase-2.html

Tweet

Subscribe to receive free email updates: